MedTrace Logo

Maintenance Therapy After Platinum-containing Chemotherapy in Patients With Recurrent Ovarian Cancer

NCT06188455 · Status: NOT_YET_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 37

Last updated 2024-01-03

No results posted yet for this study

Summary

Thirty-seven women aged 18-75 years with recurrent ovarian cancer were enrolled

Conditions

Interventions

DRUG

Fluzoparib Capsules

Oral administration of 100 mg, 2 capsules/time (50 mg/capsule), twice daily

DRUG

Apatinib Mesylate Tablets

Oral administration of 250 mg each time, 1 tablet/time (250 mg/tablet)

Sponsors & Collaborators

  • The First Affiliated Hospital of Xiamen University

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-12-01
Primary Completion
2025-12-01
Completion
2026-12-01

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06188455 on ClinicalTrials.gov